PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'P95 Epidemiology & Pharmacovigilance, Leuven, Belgium. Electronic address: marc.baay@p-95.com.\', \'University Claude Bernard Lyon, VirPath Research Laboratory, Lyon, France. Electronic address: bruno.lina@univ-lyon1.fr.\', \'Department of Global Health, Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France. Electronic address: arnaud.fontanet@pasteur.fr.\', \'Institute for Medical Immunology, Université libre de Bruxelles, Brussels, Belgium. Electronic address: arnaud.marchant@ulb.be.\', \'Vaccine R&D, CEPI, London, United Kingdom. Electronic address: melanie.saville@cepi.net.\', \'International Alliance for Biological Standardization - IABS, Geneva, Switzerland. Electronic address: philippe.sabot@iabs.org.\', \'International Alliance for Biological Standardization - IABS, Geneva, Switzerland. Electronic address: joris.vandeputte@iabs.org.\', \'International Alliance for Biological Standardization - IABS, Geneva, Switzerland. Electronic address: Pieter.neels@vaccine-advice.be.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S1045-1056(20)30137-810.1016/j.biologicals.2020.11.003
?:hasPublicationType
?:journal
  • Biologicals : journal of the International Association of Biological Standardization
is ?:pmid of
?:pmid
?:pmid
  • 33234420
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • Virology, epidemiology, immunology and vaccine development of SARS-CoV-2, update after nine months of pandemic.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all